

## REQUEST FOR APPLICATIONS

### K12 Paul Calabresi Award for Clinical Oncology

The DF/HCC K12 Internal Advisory Committee is seeking applications for the K12 Paul Calabresi Award for Clinical Oncology, entitled “Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology.” Funding for up to 5 new Scholars will be available, retroactive to September 1, 2023. Senior fellows and junior faculty, within three years of their first appointment, are eligible, provided they do not hold R01 or equivalent funding. **The deadline for applications is Friday September 15, 2023.**

The overall mission of the DF/HCC K12 Program is to identify the most talented trainees in our academic community and prepare them for careers in translational oncology research through didactic and practical experience in clinical investigation that is closely linked to laboratory research (including “wet” and “dry” lab). This K12 Program is designed exclusively for physicians (MD or MD/PhD) who have completed subspecialty clinical training in adult or pediatric hematology/oncology, or radiation oncology. Each scholar must identify a Basic Science Mentor and a Clinical Science Mentor (Scholars and Mentors must work at the same DF/HCC institution). Additional mentors from any DF/HCC institution, as well as the Broad and Koch Institutes, may be recruited to supply content-specific advice or assistance if their expertise is not well-represented in the core DF/HCC K12 faculty.

Scholar salaries can be requested up to \$100,000, in accordance with K-awardee salary guidelines, along with associated fringe benefits. The total salary requested for Scholars must be established on the base salary of a full-time, 12-month staff appointment. Scholars are required to devote a minimum of 9 person months of full-time professional effort to conducting health-related research. Up to \$30,000 (direct) may be requested annually for non-personnel expenses. Each appointment’s annual direct costs must not exceed \$138,888. A modified total direct cost F&A rate of 8% is allowable. Total costs each year must not exceed \$150,000. The performance period is September 1, 2023, through August 31, 2024. The program provides Scholars up to 3 years of support (contingent on available funds and continued Scholar eligibility).

Women and members of groups under-represented in medicine are strongly encouraged to apply.

#### The application package consists of the following components:

- Research Plan (5 pages maximum)
- Plan for Didactic Coursework (1 page) and Mentorship Plan (1 page)
- Letters of Support (Institutional Support, Clinical Mentor, Laboratory Mentor)
- Budget & Justification and Biosketches (Applicant and Mentors)

Additional information may be obtained by contacting the Program Administrator, Kelsey Laning ([klaning@mgh.harvard.edu](mailto:klaning@mgh.harvard.edu)) or the Program Director, Timothy Graubert ([tgraubert@mgh.harvard.edu](mailto:tgraubert@mgh.harvard.edu)).



A Cancer Center Designated by the  
National Cancer Institute

Beth Israel Deaconess Medical Center  
Boston Children’s Hospital  
Brigham and Women’s Hospital  
Dana-Farber Cancer Institute  
Harvard Medical School  
Harvard School of Public Health  
Massachusetts General Hospital